Farrell Michael J.

SEC source: 0001127602-24-023757 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464,169

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $245.90 - $254.06. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-24-023757 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 478,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001127602-24-022294 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 464,169

F2 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date.

SEC source: 0001127602-24-022294 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 460,071

F1 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

SEC source: 0001127602-24-021919 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,049

Underlying: ResMed Common Stock · 14,683 shares

Expires 2024-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0001127602-24-021919 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,799

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $210.31 - $219.11. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-24-021919 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001127602-24-020270 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,732

Underlying: ResMed Common Stock · 14,683 shares

Expires 2024-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-24-020270 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,799

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $192.03 - $194.73. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-24-020270 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001062993-24-013333 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,586.221

Underlying: Common Stock · 299.594 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

SEC source: 0001127602-24-018325 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,415

Underlying: ResMed Common Stock · 14,683 shares

Expires 2024-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-24-018325 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,799

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $210.58 - $213.86. The price reported above reflects the weighted average sale price.

F3 · balance_after: Includes 46.9596 shares of ResMed stock purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan.

SEC source: 0001127602-24-018325 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001062993-24-010211 · form4.xml · derivative · entry 2

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,831.928

Underlying: Common Stock · 1,068.991 shares

Expires not disclosed

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.

SEC source: 0001062993-24-010211 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,286.627

Underlying: Common Stock · 616.726 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 26.611 phantom stock units accrued on April 30, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001127602-24-014727 · form4.xml · derivative · entry 8

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,098

Underlying: ResMed Common Stock · 13,507 shares

Expires 2024-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-24-014727 · form4.xml · derivative · entry 7

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,605

Underlying: ResMed Common Stock · 1,176 shares

Expires 2024-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-24-014727 · form4.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,752

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $215.71 - $217.08. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-24-014727 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001127602-24-014727 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 441,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.

SEC source: 0001062993-24-007765 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,643.29

Underlying: Common Stock · 244.821 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 25.017 phantom stock units accrued on January 31, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-24-000256 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,373.452

Underlying: Common Stock · 266.787 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 29.421 phantom stock units accrued on October 31, 2023 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. This amount also reflects the deduction of 33.198 units to correct an error in the reporting person's Form 4 filed on October 3, 2023, in which the number of phantom stock units received by the reporting person on September 30, 2023, and the total number of phantom stock units held by the reporting person following that date, were over-reported by 33.198 units.

SEC source: 0001127602-23-028095 · form4a.xml · nonDerivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 440,752

F3 · kind: Disposition to issuer for tax withholding on vesting of Performance Restricted Stock Units granted on 11/19/2020.

SEC source: 0001127602-23-028004 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 438,633

F1 · kind: Disposition to issuer for tax withholding on vesting of Performance Restricted Stock Units granted on 11/19/2020.

SEC source: 0001127602-23-028095 · form4a.xml · derivative · entry 6

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,468

Underlying: ResMed Common Stock · 55,468 shares

Expires 2030-11-16

F5 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026.

SEC source: 0001127602-23-028095 · form4a.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: ResMed Common Stock · 3,462 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Transaction was a plan auto exercise prior to expiration.

SEC source: 0001127602-23-028095 · form4a.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,105

F2 · kind: Disposition to issuer for exercise cost of options auto-exercised under the plan.

SEC source: 0001127602-23-028095 · form4a.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,448

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Original form amended to include a plan provision auto-exercise prior to option grant expiration.

SEC source: 0001127602-23-028004 · form4.xml · derivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,468

Underlying: ResMed Common Stock · 55,468 shares

Expires 2030-11-16

F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026.

SEC source: 0001127602-23-027688 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,462

Underlying: ResMed Common Stock · 5,678 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-23-027688 · form4.xml · nonDerivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,986

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $147.92 to 153.51. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-23-027688 · form4.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 446,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

SEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 440,986

F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022.

F4 · balance_after: Includes 78.152 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan.

SEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,167

F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021.

SEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 446,205

F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020.

SEC source: 0001127602-23-026027 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,140

Underlying: ResMed Common Stock · 5,675 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options are exercisable 1/3 each year beginning 1 year from date of grant.

SEC source: 0001127602-23-026027 · form4.xml · nonDerivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 449,360

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $139.745 to 141.56. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-23-026027 · form4.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

SEC source: 0001062993-23-018797 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,110.442

Underlying: Common Stock · 320.91 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 21.696 phantom stock units accrued on July 31, 2023 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001127602-23-024408 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,815

Underlying: ResMed Common Stock · 5,675 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F3 · derivative.exercise_date: Options are exercisable 1/3 each year beginning 1 year from date of grant.

SEC source: 0001127602-23-024408 · form4.xml · nonDerivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 449,360

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $145.09 to 148.07. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-23-024408 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

SEC source: 0001127602-23-022925 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 449,360

F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

SEC source: 0001127602-23-022774 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,490

Underlying: ResMed Common Stock · 5,675 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-23-022774 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 436,930

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $181.30 to 183.85. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-23-022774 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 442,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

SEC source: 0001127602-23-020982 · form4.xml · derivative · entry 5

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,165

Underlying: ResMed Common Stock · 5,675 shares

Expires 2023-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year.

SEC source: 0001127602-23-020982 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 436,930

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $220.20 to 222.46. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-23-020982 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 442,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.